FDA’s Temple: Better Meta-Analyses Needed Ahead Of Agency Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Senior FDA officials call for prospective planning and transparency in meta-analysis conduct; they also discuss potential for a “refuse-to-file” type of standard for meta-analyses that don’t meet certain format and content standards worthy of agency consideration.